Gasgoo Munich- LinkerBot has officially completed a strategic acquisition of the Jingling Zhikang team. The two parties will deepen collaboration on intelligent bionic hands, rehabilitation aids, and human-computer interaction, aiming to transform high-performance prosthetics from "custom items for the few" into "accessible tools for the many."
A dominant player in the dexterous hand sector, LinkerBot has already established an industrial foundation spanning high degrees of freedom, control systems, and mass manufacturing. Its Linker Hand series boasts a wide price range, covering 6,000 to 100,000 yuan, and is currently widely used by leading general-purpose robot manufacturers and top global research institutions.
Image Credit: LinkerBot
Although a newcomer, Jingling Zhikang has built a solid track record in ergonomic adaptation, force-control interaction, and rehabilitation engineering. Co-founder and CEO Song Zhiwei is a seasoned AI veteran who previously held roles at Lenovo, Asus China, and Ingram Micro China, bringing deep experience in strategic management, operations, and marketing, along with a global perspective.
The R&D team led by Co-founder and CTO Zhu Zitao consists of core members from Professor Chen Wenming’s team at Fudan University. They possess mature technology and practical experience in biomechanics, humanoid haptics, exoskeletons, array-motor bionic actuation, natural human-machine force control, human motion modeling, and the engineering of civilian rehabilitation scenarios.
This merger represents a complementary pairing of "hardware mass production capabilities" and "rehabilitation implementation capabilities." LinkerBot fills the gap in mass manufacturing for Jingling Zhikang, while Jingling Zhikang opens up real-world rehabilitation scenarios for LinkerBot.
On the price front, imported intelligent bionic hands have long sold for 300,000 to 500,000 yuan, while domestic versions cost over 100,000 yuan—sums that the vast majority of families with disabilities cannot afford.
LinkerBot founder Zhou Yongming made it clear: relying on independent R&D across the entire chain and scaled manufacturing, the company will push the price of high-end bionic hands down to the 30,000 to 50,000 yuan range. Within the next three years, prices could even drop below 10,000 yuan. At the same time, products will focus on improving haptic feedback, wearing comfort, and ease of operation.
If this pricing structure can be implemented while maintaining stable profits, intelligent bionic hands will truly transform from high-end medical equipment into mass consumer goods. By then, the competitive logic of the entire rehabilitation assistive sector is likely to be redefined.
